Levofloxacin has predominant renal elimination. As such, dose reductions are necessary in patients with significant renal dysfunction [ 6 ]. Metabolism does not involve the P system and Doose et al. However, CyA is a potent inhibitor of P-glycoprotein—a drug transporter which reduces cellular concentrations of certain drugs [ 8 ]. In this way, CyA may actually prolong tissue levofloxacin concentrations, especially if levofloxacin dosage is inappropriately high.
Quinolones are known to cause tendon rupture. Google Scholar. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
Sign In or Create an Account. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents References. Levofloxacin and rhabdomyolysis in a renal transplant patient.
Asher Korzets , Asher Korzets. Oxford Academic. Uzi Gafter. Correspondence and offprint requests to : Prof. Email: uzig clalit. Drugs 58 , Suppl. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account.
Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. Materials and methods. Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. Oxford Academic. Google Scholar. Renate Thalhammer-Scherrer. Gottfried J. Heidrun Losert. Rainer Schmid.
Thomas Staudinger. Florian Thalhammer. Revision received:. Select Format Select format. Permissions Icon Permissions. Abstract The present study was performed to analyse the pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration CVVH with a high-flux polyamide membrane. Pharmacokinetic data of levofloxacin in 12 study patients.
Elimination constant k el 0. Open in new tab. Median C max -MIC90 ratios were 10 or greater for Haemophilus influenzae, Moraxella catarrhalis, Enterobacter cloacae, and Klebsiella pneumoniae, approximately 5 for Streptococcus pneumoniae, and less than 1 for Pseudomonas aeruginosa.
Abstract Background: No published data are available describing the pharmacokinetics of intravenous levofloxacin in patients with end-stage renal disease ESRD. Intradialytic Drug Removal by Short-daily Hemodialysis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.
Federal Government. Read our disclaimer for details. Results First Posted : March 25, Last Update Posted : March 25, Study Description. The following are the specific aims: Determine the interdialytic pharmacokinetics of vancomycin, gentamicin, and levofloxacin by short-daily HD.
Determine the extent of vancomycin removal when administered during the last hour of short-daily HD. Develop drug-dosing guidelines for vancomycin, gentamicin and levofloxacin for patients receiving short-daily HD.
Detailed Description:. Drug Information available for: Gentamicin Vancomycin Levofloxacin. FDA Resources. Arms and Interventions. Other Names: Vancocin vancomycin Levaquin levofloxacin Gentamicin gentamicin. Outcome Measures.
Primary Outcome Measures : Intradialytic Clearance of Levofloxacin, Gentamicin and Vancomycin in Patients Receiving Short-daily Hemodialysis [ Time Frame: Serum concentrations for each drug will be determined from blood samples at 0 pre-infusion , 30, 60 minutes end of infusion.
Eligibility Criteria. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.
0コメント